1. Hughes ZA, Stanford SC. Increased noradrenaline efflux induced by local infusion of fluoxetine in the rat frontal cortex. Eur J Pharmacol 1996; 317:83-90.

2. Chen N-H, Reith MEA. Effects of locally applied cocaine, lidocaine and various uptake blockers in monoamine transmission in the ventral tegmental area of freely moving rats: A microdialysis study on monoamine interrelationships. J Neurochem 1994; 63:1701-1713.

3. Jordan S, Kramer GL, Zukas PK et al. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine and fluvoxamine. Synapse 1994; 18:294-297.

4. Perry KW, Fuller RW. Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats. J Neural Transm 1997; 104:953-966.

5. Matsumoto M, Yoshioka M, Togashi H et al. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther 1995; 272:1044-1051.

6. Gobert A, Rivet J-M, Cistarelli L et al. a2-Adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 1997; 69:2616-2619.

7. Paez X, Liebowitz S. Changes in extracellular PVN monoamines and macronutrient intake after idazoxan or fluoxetine injection. Pharmacol Biochem Behav 1993; 46: 933-941.

8. Hajos-Korcsok E, Sharp T. Personal communication. 1998.

9. Benloucif S, Galloway MP. Facilitation of dopamine release in vivo by serotonin agonists: Studies with microdialysis. Eur J Pharmacol 1991; 200:1-8.

10. Chen N-H, Reith MEA. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (± )-8-hydroxy-2-(di-n-propylamino)tetralin. J Neurochem 1995; 64:1585-1597.

11. Perry KW, Fuller RW. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci 1992; 50:1683-1690.

12. Li X-M, Perry KW, Fuller RW. On the in vivo modulation of neostriatal dopamine release by fluoxetine and 5-hydroxy-L-tryptophan in conscious rats. J Pharm Pharmacol 1996; 48:825-828.

13. Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol 1995; 281:255-261.

14. Hughes ZA, Stanford SC. Evidence from microdialysis and synaptosomal studies of rat cortex for noradrenaline uptake sites with different sensitivities to SSRIs. Br J Pharmacol 1998; 124:1141-1148.

15. Sammet S, Graefe K-H. Kinetic analysis of the interaction between noradrenaline and Na+ in neuronal uptake: Kinetic evidence for cotransport. Naunyn-Schmiedeberg's Arch Pharmacol 1979; 309:99-107.

16. Carlsson l, Abrahamson T. Characterization of the inhibitory effect of some antidepressant drugs on the outward transport of norepinephrine in the ischemic myocardium. J Pharmacol Exp Ther 1988; 247:715-720.

17. Langeloh A, Bonisch H, Trendelenburg U. The mechanism of the 3H-noradrenaline releasing effect of various substrates of uptake1: A multifactorial induction of outward transport. Naunyn-Schmiedeberg's Arch Pharmacol 1987; 336:602-610.

18. Povlock SL, Amara SG. The structure and function of norepinephrine, dopamine and serotonin transporters. In: Neurotransmitter Transporters, Structure, Function and Regulation. Reith MEA, ed. Totowa, New Jersey; Humana Press Inc., 1997:1-28.

19. Blakely RD, Ramamoorthy S, Qian Y et al. Regulation of antidepressant-sensitive serotonin receptors. In: Reith, MEA. ed. Neurotransmitter Transporters: Structure, Function and Regulation. Totowa, New Jersey: Humana Press Inc., 1997:29-72.

20. Rudnick G. Mechanisms of biogenic amine neurotransmitter transporters. In: Reith MEA, ed. Neurotransitter Transporters: Structure, Function and Regulation. Totowa, New Jersey: Humana Press Inc., 1997:73-100.

21. Ramamoorthy S, Bauman AL, Moore KR et al. Antidepressants- and cocaine-sensitive human serotonin receptor transporter: Molecular cloning, expression and chromosomal localization, Proc Natl Acad Sci USA 1993; 90:2542-2546.

22. Austin MC, Bradley CC, Mann JJ et al. Expression of serotonin transporter messenger RNA in the human brain. J Neurochem 1994; 62:2362-2367.

23. Barker El, Blakely RD. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Molec Pharmacol 1996; 50:957-965.

24. Sur C, Betz H, Schloss P. A single serine residue controls the cation dependence of substrate transport by the rat serotonin transporter. Proc Natl Acad Sci USA 1997; 94:7639-7644.

25. Rosenthal NE, Nazzanti CM, Barnett RL et al. Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder. Mol Psychiatry 1998; 3:175-177.

26. Jayanthi LD, Prasad PD, Ramamoorthy S et al. Sodium and chloride-dependent cocaine-sensitive, high-affinity binding of nisoxetine to the human placental norepinephrine transporter. Biochemistry 1993; 32:12178-12185.

27. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991; 350:350-353.

28. Gu H, Wall SC, Rudnick G. Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics and ion dependence. J Biol Chem 1994; 269; 7124-7130.

29. Pifl C, Hornykiewicz O, Giros B et al. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human nora-drenaline and human dopamine transporter. J Pharmacol Exp Ther 1996; 277:1437-1443.

30. Giros, B, Mestikawt S, Godinot N et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molec Pharmacol 1992; 42:383-390.

31. Tatsumi M, Groshan K, Blakely RD et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340:249-258.

32. Owens MJ, Morgan WN, Plott SJ et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283:1305-1322.

33. Pristupa ZB, Wilson JM, Hoffman BJ et al. Pharmacological heterogeneity of the cloned and native human dopamine transporter: Disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Molec Pharmacol 1994; 45:125-135.

34. Buck KJ, Amara SG. Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. Molec Pharmacol 1995; 46:1030-1037.

35. Erreboe I, Plenge P, Mellerup ET. Differences in brain 5-HT transporter dissociation rates among animal species. Pharmacol Toxicol 1995; 76:376-379.

36. Plenge P, Mellerup ET An affinity-modulating site on neuronal monoamine transport proteins. Pharmacol Toxicol 1997; 80:197-201.

37. Martel F, Azevedo I, Osswald W. Uptake of 3H-catecholamines by rat liver cells occurs mainly through a system which is distinct from uptake1 or uptake2. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350:130-142.

38. Russ H, Staudt K, Martel F et al. The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur J Neurosci 1996; 8:1256-1264.

39. Paterson IA, Hertz L. Sodium-independent transport of noradrenaline in mouse and rat astrocytes in primary culture. J Neurosci Res 1989; 23:71-77.

40. Paczkowski NJ, Vuocolo HE, Bryan-Lluka LJ. Conclusive evidence for distinct transporters for 5-hydroxytryptamine and noradrenaline in pulmonary endothelial cells of the rat. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 353:423-430.

41. Michel M, Hiemke C, Ghraf R. Preferential uptake of norepinephrine into dopaminergic terminals of a synaptosomal preparation from rat cerebral cortex. Brain Res 1984; 301:149-152.

42. Wong DT, Bymaster FP, Horng JS et al. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenyl-propylamine. J Pharmacol Exp Ther 1975; 193:804-811.

43. Fleckenstein AE, Beyeler ML, Jackson JC et al. Methamphetamine-induced decrease in tryptophan hydroxylase activity: Role of 5-hydroxytryptaminergic transporters. Eur J Pharmacol 1997; 324:179-186.

44. Chen N-H, Reith MEA. Role of axonal and somatodendritic monoamine transporters in action of uptake blockers. In: Neurotransmitter Transporters, Structure, Function and Regulation. Reith MEA, ed. Totowa, New Jersey; Humana Press Inc., 1997:345-391.

45. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52:1023-1029.

46. Stanford SC Prozac: Panacea or puzzle? Trends Pharmacol Sci 1996; 17:150-154.

47. Wong DT, Horng JS, Bymaster FP. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci 1974; 15:471-479.

48. Cheng CHK, Costall B, Naylor RJ et al. The effect of 5-HT receptor ligands on the uptake of [3H]5-hydroxytryptamine into rat cortical synaptosomes. Eur J Pharmacol 1993; 239:211-214.

49. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984; 104:277-286.

50. Cheetham SC, Viggers JA, Slater NA et al. [3H] paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: Effect of administration of various antidepressant treatments. Neuropharmacology 1993; 32:737-743.

51. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 1987; 93:193-200.

52. Cool DR, Liebach FH, Ganapathy V. Interaction of fluoxetine with the human placental serotonin transporter. Biochem Pharmacol 1990; 40:2161-2167.

53. Harms HH. The antidepressant agents desipramine, fluoxetine, fluvoxamine and norzimelidine inhibit uptake of [3H]noradrenaline and [3H]5-hydroxytryptamine in slices of human and rat cortical brain tissue. Brain Res 1983; 275:99-104.

54. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996; 31:444-469.

55. Amsterdam JD, Fawcett J, Quitkin FMet al. Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study. Am J Psychiatry 1997; 154:963-969.

56. Caccia S, Fracasso C, Garattini S et al. Effects of short- and long-term administration of fluoxetine on the monoamine content of rat brain. Neuropharmacology 1992; 31:343-347.

57. Dailey JW, Yan, QS, Mishra PKet al. Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. J Pharmacol Exp Ther 1992; 260:533-540.

58. Hyttel J, Over0 KF, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology 1984; 83:20-27.

59. Engberg G. Citalopram and 8-OH-DPAT attenuate nicotine-induced excitation of central noradrenaline neurons. J Neural Transm 1992; 89:149-154.

60. Akaoka H, Aston-Jones G. Indirect, serotonergic agonists attenuate neuronal opiate withdrawal. Neurosci 1993; 54:561-565.

61. Brady LS. Stress, antidepressant drugs and the locus coeruleus. Brain Res Bull 1994; 35:545-556.

62. Curtis AL, Valentino RJ. Corticotropin-releasing factor neurotransmission in locus coeruleus: A possible site of antidepressant action. Brain Res Bull 1994; 35:581-587.

63. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology 1994; 114:559-565.

64. Jenck F, Moreau J-L, Mutel V et al. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993; 231:223-229.

65. Narita N, Hashimoto K, Tomitaka S et al. Interactions of selective serotonin reuptake inhibitors with subtypes of o receptors in rat brain. Eur J Pharmacol 1996; 307:117-119.

66. Leonard BE. The potential contribution of sigma receptors in antidepressant actions. In: Skolnick P ed. Antidpressants: New Pharmacological Strategies. Totowa, New Jersey; Humana Press, 1997:159-172.

67. Mongeau R, De Montigny C, Blier P. Activation of 5-HT3 receptors enhances the electrically evoked release of [3H]noradrenaline in rat brain limbic structures. Eur J Pharmacol 1994; 256:269-279.

68. Suzuki M, Matsuda T, Asano S et al. Increase of noradrenaline release in the hypothalamus of freely-moving rat by postsynaptic 5-hydroxytrypamine1A receptor activation. Br J Pharmacol 1995; 115:703-711.

69. Blandina P, Goldfarb J, Walcott et al. Serotonergic modulation of the release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther 1991; 256:341-347.

70. Goldfarb J, Walcott J, Blandina P. Serotonergic modulation of L-glutamic acid-evoked release of endogenous norepinephrine from rat hypothalamus. J Pharmacol Exp Ther 1993; 267:45-50.

71. Feuerstein TJ, Herrting G. Serotonin (5-HT) enhances hippocampal noradrenaline (NA) release: evidence for facilitatory 5-HT receptors within the CNS. Naunyn-Schmiedeberg's Arch Pharmacol 1986; 333:191-197.

72. Kidd EJ, Laporte AM, Langlois K et al. 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Res 1993; 612:289-298.

73. Allgaier C, Warnke P, Stangl AP et al. Effects of 5-HT receptor agonists on depolarization-induced [3H]-noradrenaline release in rabbit hippocampus and human neocortex. Br J Pharmacol 1995; 116:1769-1774.

74. Luppi PH, Aston-Jones G, Akaoka H et al. Afferent projections to the rat locus coeruleus demonstrated by retrograde and anterograde tracing with cholera-toxin B subunit and Phaseolus vulgaris leucoagglutinin. Neuroscience 1995; 65:119-160.

75. Vertes RP, Kocsis B. Projections of the dorsal raphe nucleus to the brainstem: PHA-L analysis in the rat. J Comp Neurol 1994; 340:11-26.

76. Aston-Jones G, Shipley MT, Chouvet G et al. Afferent regulation of locus coeruleus neurons: Anatomy, physiology and pharmacology. Prog Brain Res 1991; 88:47-75.

77. Renaud B, Buda M, Lewis BD et al. Effects of 5,6-dihydroxytryptamine on tyrosine hydroxylase activity in central catecholaminergic neurons of the rat. Biochem Pharmacol 1975; 24:1739-1742.

78. Haddjeri N, de Montigny C, Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxytryptamine system. Br J Pharmacol 1997; 120:865-875.

79. Reader TA, Briere R, Grondin L et al. Effects of p-chlorophenylalanine on cortical monoamines and on the activity of noradrenergic neurons. Neurochem Res 1986; 11:1025-1035.

80. Ferron A. Modified coeruleo-cortical noradrenergic neurotransmission after serotonin depletion by PCPA: electrophysiological studies in the rat. Synapse 1988; 2:532-536.

81. Shiekhattar R, Aston-Jones G. Sensory responsiveness of brain noradrenergic neurons is modulated by endogenous brain serotonin. Brain Res 1993; 623:72-76.

82. Aston-Jones G, Akaoka H, Chariety P et al. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J Neurosci 1991; 11:760-769.

83. Engberg G. A metabolite of buspirone increases locus coeruleus activity via a2-receptor blockade. J Neural Transm 1989; 91-98.

84. Gorea E, Davenne D, Lanfumey L et al. Regulation of noradrenergic coerulean neuronal firing mediated by 5-HT2 receptors: Involvement of the prepositus hypoglossal nucleus. Neuropharmacol 1991; 30:1309-1318.

85. Aston-Jones G, Shipley MT, Chouvet G et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 1991; 88:47-75.

86. Hamamura T, Lee Y, Fujiwara Y et al. Serotonin1A receptor agonists induce Fos protein expression in the locus coeruleus of the conscious rat. Brain Res 1997; 759:156-159.

87. Done CJG, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: Microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 1994; 33:411-421.

88. Hajos-Korcsok E, McQuade R, Sharp T. Influence of 5-HT1A receptors on central noradrenergic activity: Microdialysis studies using (±) MDL 73005EF and its enantiomers. Neuropharmacology 1999; 38:299-306.

89. Dalley JW, Mason K, Stanford SC. Increased levels of extracellular noradrenaline in the frontal cortex of rats exposed to naturalistic environmental stimuli: Modulation by acute systemic administration of diazepam or buspirone. Psychopharmacology 1996; 127:47-54.

90. Hajos-Korcsok E, Sharp T. 8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT1A and dopamine D1 receptors. Eur J Pharmacol 1996; 314:285-291.

91. Rasmussen K, Aghajanian GK. Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists. Brain Res 1986; 385:395-400.

92. Gorea E, Adrien J Serotonergic regulation of noradrenergic coerulean neurons: Electrophysiological evidence for the involvement of 5-HT2 receptors. Eur J Pharmacol 1988; 154:285-291.

93. Chiang C, Aston-Jones G. A 5-hydroxytryptamine2 agonist augments y-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neurons. Neurosci 1993; 54:409-420.

94. Done CJG, Sharp T. Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol 1992; 107:240-245.

95. Ennis C, Kemp JD, Cox B. Characterization of inhibitory 5-hydroxytrypamine receptors that modulate dopamine release in the striatum. J Neurochem 1981; 36:1515-1520.

96. Muramatsu M, Tamaki-Ohashi J, Usuki C et al. 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat striatal slices. Eur J Pharmacol 1988; 153:89-95.

97. Blandina P, Goldfarb J, Craddock-Royal B et al. Release of endogenous dopamine by stimulation of 5-hydroxytryptamine3 receptors in rat striatum. J Pharmacol Exp Ther 1989; 251:803-809.

98. Yadid G, Pacak K, Kopin IJ et al. Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmaol Exp Ther 1994; 270:1158-1165.

99. Galloway MP, Suchowski CS, Keegan MJ et al. Local infusion of the selective 5-HT-1b agonist, CP-93,129 facilitates striatal dopamine release in vivo. Synapse 1993; 15:90-92.

100. Chen N-H, Reith MEA. [3H] Dopamine and [3H] serotonin release in vitro induced by electrical stimulation in A9 and A10 dopamine regions of rat brain: Characterization and responsiveness to cocaine. J Pharmacol Exp Ther 1993; 267:379-389

101. Jacocks HM, Cox BM. Serotonin-stimulated release of [3H]dopamine via reversal of the dopamine transporter in rat striatum and nucleus accumbens: A comparison with release elicited by potassium, N-methyl-D-aspartic acid, glutamic acid and D-amphetamine. J Pharmacol Exp Ther 1992; 262:356-364..

102. Parsons LH, Justice JB. Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Brain Res 1993; 606:195-199.

103. Yi S-J, Gifford AN, Johnson KM. Effect of cocaine and 5-HT3 receptor antagonists on 5-HT-induced [3H]dopamine release from rat striatal synaptosomes. Eur J Pharmacol 1991; 199:185-189.

104. Simon JR, Ghetti B. Is there a significant somatodendritic uptake of dopamine in the substantia nigra? Evidence from the weaver mutant mouse. Neurochem Int 1993; 22:471-477.

105. Carboni E. Tanda GL, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 1990; 55:1067-1070.

106. Chen J, van Praag HM, Gardner EL. Activation of 5-HT3 receptor by 1-phenylbiguanide increases dopamine release in the rat nucleus accumbens. Brain Res 1991; 543:354-357.

107. Chen J, Paredes W, van Praag H et al. Presynaptic dopamine release is enhanced by 5-HT receptor activation in medial prefrontal cortex of freely moving rats. Synapse 1992; 10:264-266.

108. Benloucif S, Keegan MJ, Galloway MP Serotonin-facilitated dopamine release in vivo: Pharmacological characterization. J Pharmacol Exp Ther 1993; 265:373-377.

109. Bonhomme N, de Deurwaerdere P, Le Moal N et al. Evidence for 5-HT4 receptor involvement in the enhancement of striatal dopamine release induced by serotonin: A microdialysis study in the halothane-anesthetized rat. Neuropharmacology 1995; 34:269-279.

110. Steward LJ, Ge J, Stowe RL et al. Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo. Br J Pharmacol 1996; 117:55-62.

111. Nurse B, Russell VA, Taljaard JJF. Characterization of the effects of serotonin on the release of [3H]dopamine from rat nucleus accumbens and striatal slices. Neurochem Res 1988; 13:403-407.

112. De Belleroche JS, Bradford HF. Presynaptic control of the synthesis and release of dopamine from striatal synaptosomes: A comparison between the effects of 5-hydroxytryptamine, acetylcholine and glutamate. J Neurochem 1980; 35:1227-1234.

113. De Deurwaerdere P, Bonhomme N, Lucas G et al. Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. J Neurochem 1996; 66:210-215.

114. Schmidt CJ, Black CK. The putative 5-HT3 agonist phenylbiguanide induces carrier-mediated release of [3H]dopamine. Eur J Pharmacol 1989; 167:309-310.

115. Prisco S, Pagannone S, Esposito E. Serotonin-dopamine interaction in the rat ventral tegmental area: An electrophysiological study in vivo. J Pharmacol Exp Ther 1994; 271:83-90.

116. Yoshimoto K, McBride WJ. Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat. Neurochem Res 1992; 17:401-407.

117. Beasley CM, Masica DN, Potvin JH Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology 1992; 107:1-10.

118. Fozard JR, Mwaluko GMP. Mechanism of the indirect sympathomimetic effect of 5-hydroxytryptamine on the isolated heart of the rabbit. Br J Pharmacol 1976; 57:115-125.

Natural Depression Cures

Natural Depression Cures

Are You Depressed? Heard the horror stories about anti-depressants and how they can just make things worse? Are you sick of being over medicated, glazed over and too fat from taking too many happy pills? Do you hate the dry mouth, the mania and mood swings and sleep disturbances that can come with taking a prescribed mood elevator?

Get My Free Ebook

Post a comment